论文部分内容阅读
作者通过观察4种促凝剂(花生四烯酸、肾上腺素、ADP、胶原蛋白)的反应,来测定血小板聚集反应(PA)的抑制程度,借此评价阿司匹林(ASA)在防治急性卒中中的生物学效应。门诊病人113例(男46例,女67例),平均年龄男61.8岁,女60.1岁,均为预防卒中而服 ASA 者。对确定为研究对象者,嘱其继续服用正在服的剂量,在第15天做 PA 检查。依照 PA 结果调整 ASA剂量:若 PA 完全抑制,则病人仍服原剂量;若 PA部分抑制,则将 ASA 剂量增加一倍,直至 PA 完全抑制或剂量达到1300mg/d。结果107例剂量≤
The authors measured the inhibition of platelet aggregation (PA) by observing the responses of four coagulants (arachidonic acid, epinephrine, ADP, collagen) to evaluate the efficacy of aspirin (ASA) in the prevention and treatment of acute stroke Biological effects. There were 113 outpatients (46 males and 67 females) with an average age of 61.8 years and 60.1 years of age, both of whom were ASDs for stroke prevention. For those who were identified as subjects, they were instructed to continue taking the dose they were serving and PA tests were performed on the 15th day. Adjusted ASA dose according to PA results: If PA is completely inhibited, the patient is still given the original dose; if PA is partially inhibited, the ASA dose is doubled until the PA is completely inhibited or the dose reaches 1300 mg / d. 107 cases of dose ≤